SCHEMBL20135665

SCHEMBL20135665

CC(C)C1(c2ccc(C(=O)N3CCN(c4ccc5ccccc5n4)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.57
ALDH1A1 P00352 6/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
HRH3 Q9Y5N1 4/20 0.44
SORD Q00796 1/20 0.41
HTR3E A5X5Y0 2/20 0.41
HTR3B O95264 2/20 0.41
CYP1A2 P05177 2/20 0.41
HTR3A P46098 2/20 0.41
HTR3D Q70Z44 2/20 0.41
HTR3C Q8WXA8 2/20 0.41
THPO P40225 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
FASN P49327 1/20 0.41
RECQL P46063 1/20 0.41
MGLL Q99685 2/20 0.41
CYP3A4 P08684 2/20 0.40
HSD17B10 Q99714 2/20 0.40
CRBN Q96SW2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135662 1.00 KDM4E (0.57) KDM4EALDH1A1SMN1; SMN2HRH3SORD
SCHEMBL29688871 1.00 KDM4E (0.57) KDM4EALDH1A1SMN1; SMN2HRH3SORD
SCHEMBL29688606 0.83 ADAMTS5 (0.55) ALDH1A1HSD17B10CRBNMEN1POLB
SCHEMBL20134996 0.83 ADAMTS5 (0.55) ALDH1A1HSD17B10CRBNMEN1POLB
SCHEMBL20134998 0.83 ADAMTS5 (0.55) ALDH1A1HSD17B10CRBNMEN1POLB
SCHEMBL20135409 0.83 KMT2A (0.61) ALDH1A1SMN1; SMN2CYP1A2MGLLCRBN
SCHEMBL20135410 0.83 KMT2A (0.61) ALDH1A1SMN1; SMN2CYP1A2MGLLCRBN
SCHEMBL20135673 0.79 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2CRBNMEN1KMT2A
SCHEMBL20135672 0.79 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2CRBNMEN1KMT2A
SCHEMBL20135142 0.78 KDM5A (0.47) CRBNMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 KDM4E 725/4885ALDH1A1 584/4885SMN1; SMN2 2532/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 KDM4E 723/4885ALDH1A1 610/4885SMN1; SMN2 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.